Insmed reported $15.58B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Cytokinetics USD 8.19B 420M Mar/2026
DBV Technologies USD 274M 17M Sep/2025
Gilead Sciences USD 172.99B 20.71B Mar/2026
Heron Therapeutics USD 238M 7M Dec/2025
Insmed USD 35.3B 1.82B Mar/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Vertex Pharmaceuticals USD 113.58B 1.44B Mar/2026